Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
The Collaboration As a large-cap ($51.9B) biopharma developing innovative therapeutics for diverse chronic diseases affecting different organ systems, Takeda Pharmaceuticals ( OTCPK:TKPHF ) ( TAK ) was expected to jump on the NASH bandwagon. In Q4/2017, Takeda initiated the first stage of ...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...
Five short months ago, Sangamo ( SGMO ) released their 2018 results , providing a program review which refocused development priorities. Gene editing trials for hemophilia B, MPS I and MPS II were put on hold. Gene and cell therapies became the more immediate opportunities. Hemophilia A becam...
Revenue 849.1 billion yen, up +88.8% versus prior year mainly due to acquisition of Shire, with solid performance of 14 global growth brands Strong start with Core Operating Profit* of 283.0 billion, up +142.3% versus FY2018 Q1 and Underlying Core Operating Profit Margin of 32.4%...
Takeda Pharmaceutical Company Limited (“Takeda”) ( TOKYO: 4502/NYSE: TAK ) today announces that the Takeda Board of Directors has approved key performance indicators (KPIs) to be included in both the company’s short-term and long-term incentive plans for fiscal year 2019,...
Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced top-line re...
Chembio Diagnostics (NASDAQ: CEMI ) will collaborate with Takeda (NYSE: TAK ) unit Shire Human Genetic Therapies to develop an point-of-care (POC) diagnostic test for an undisclosed biomarker. More news on: Chembio Diagnostics, Inc., Takeda Pharmaceutical Company Limited, Healthcare stoc...
Aimed at trimming debt after its $59B takeout of Shire plc, Takeda Pharmaceutical Company ( TAK -2.8% ) is seeking suitors for a lineup of drugs it sells in Western Europe that could fetch €1.5B ($1.68B) according to Reuters . More news on: Takeda Pharmaceutical Company Limited, ...
by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile in Patients with Newly Diagnosed Stage IIb/III/IV Classical Hodgkin Lymphoma vs eBEACOPP, a Current Standard of Care i...
cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90% 1,2 If Approved in the European Union, rADAMTS13 Will Be the First and Only Recombinant ADAMTS13 Enzyme Replacement The...
2024-05-24 09:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...